Nautilus Biotechnolgy Stock
Nautilus Biotechnolgy, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sujal Patel
- Employees
- 127
- Market cap
- $262 M
- IPO
- 07/08/2020
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents,…
Nautilus Biotechnolgy stock: price history
1D
-4.6%
1W
-8.4%
1M
+111.9%
6M
-32.0%
YTD
+5.6%
1Y
+92.5%
2Y
-30.4%
5Y
-63.9%
10Y
–
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~15% stronger price swings than usual
Ask the agents about Nautilus Biotechnolgy
Analyst assessment of Nautilus Biotechnolgy
PRICE TARGET LOW
US$3.50
CONSENSUS
US$3.50
MEDIAN
US$3.50
PRICE TARGET HIGH
US$3.50
0
STRONG BUY
3
BUY
1
HOLD
1
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 27/02/2026
Nautilus Biotechnolgy stock metrics
P/E
-4.58
P/B
1.99
EV/EBITDA
-5.15
RETURN ON EQUITY
-11.0%
NET MARGIN
-7,615.3%
DEBT/EQUITY
0.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
44.0%
FLOAT SHARES
55,986,033
AVG. DAILY VOLUME (30D)
6,752,540
Insider transactions (SEC)
AH Equity Partners Bio II, L.L.C.
AH Equity Partners Bio II, L.L.C.
Institutional holders
Comparable stocks
Frequently asked questions about Nautilus Biotechnolgy stock
What does Nautilus Biotechnolgy do?
Nautilus Biotechnolgy, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sujal Patel, the company employs around 127 people.
The IPO was on 07/08/2020; the stock trades on NASDAQ under the ticker NAUT.
What do analysts say about Nautilus Biotechnolgy stock?
5 analysts rate the stock, the consensus is Buy (as of 27/02/2026).
The average price target is US$3.50, ranging from US$3.50 to US$3.50, with a median of US$3.50.
This is an external assessment, not a statement by Market Jury.
When does Nautilus Biotechnolgy report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 15% stronger than usual.
Does Nautilus Biotechnolgy pay a dividend?
No, Nautilus Biotechnolgy currently does not pay a dividend.
Which stocks are comparable to Nautilus Biotechnolgy?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nautilus Biotechnolgy stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nautilus Biotechnolgy against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.